THJ-018 (SGT-17) is a synthetic cannabinoid that is the indazole analogue of JWH-018 and has been sold online as a designer drug.[1][2]

Pharmacology

THJ-018 acts as a full agonist with a binding affinity of 5.84 nM at CB1 and 4.57 nM at CB2 cannabinoid receptors.[3]

Legality

THJ-018 is an Anlage II controlled drug in Germany.[4] It is also banned in Sweden.[5]

See also

References

  1. ^ "THJ-018". Cayman Chemical. Retrieved 9 July 2015.
  2. ^ Diao X, Wohlfarth A, Pang S, Scheidweiler KB, Huestis MA (January 2016). "High-Resolution Mass Spectrometry for Characterizing the Metabolism of Synthetic Cannabinoid THJ-018 and Its 5-Fluoro Analog THJ-2201 after Incubation in Human Hepatocytes". Clinical Chemistry. 62 (1): 157–69. doi:10.1373/clinchem.2015.243535. PMID 26430074.
  3. ^ Hess C, Schoeder CT, Pillaiyar T, Madea B, Müller CE (2016). "Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice". Forensic Toxicology. 34 (2): 329–343. doi:10.1007/s11419-016-0320-2. PMC 4929166. PMID 27429655.
  4. ^ "Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz - BtMG) Anlage II (zu § 1 Abs. 1) (verkehrsfähige, aber nicht verschreibungsfähige Betäubungsmittel)" (in German). Retrieved 9 July 2015.
  5. ^ "Cannabinoider föreslås bli klassade som hälsofarlig vara" (in Swedish). Folkhälsomyndigheten. Retrieved 9 July 2015.